Cost-effectiveness of Crohn’s disease post-operative care

Table 1 Health care utilization data extracted for health economic assessment

Health care utilization data extracted for health economic assessment
Number and type of consultations with gastroenterologists or other medical specialists for reasons related to Crohn’s disease.
Visits to primary care providers (general practitioners).
Visits to allied health care providers
Investigations related to Crohn’s disease
Visits to the emergency department
Hospital admissions < 1 d (day procedures)
Hospital admission ≥ 1 d
Current prescription medicine use related to Crohn’s disease

Table 2 Demographics n (%)

	Health economic sub-group	Entire POCER study cohort	P value
	n = 60	n = 174
n (male)	24 (40)	78 (45)	0.516
Age > 40 yr	24 (40)	68 (39)	0.900
Age, median	37	36
Age at diagnosis
≤ 16 yr	4 (7)	19 (11)	0.340
17-40 yr	49 (81)	134 (77)	0.451
> 40 yr	7 (12)	21 (12)	0.934
Duration of Crohn's disease ≥ 10 yr	29 (48)	60 (34)	0.154
Disease location at surgery:
Ileum only (L1)	33 (55)	95 (55)	0.957
Colon only (L2)	3 (5)	11 (6)	0.710
Ileum and colon (L3)	21 (35)	68 (39)	0.575
Disease phenotype at surgery:
B1 (Inflammatory)	5 (8)	17 (10)	0.742
B2 (Stricture)	18 (30)	62 (36)	0.428
B3 (Penetrating)	37 (62)	95 (55)	0.341
Indication for surgery:
Failure of drug therapy	12 (20)	38 (22)	0.764
Obstruction	14 (23)	50 (29)	0.418
Perforation	34 (57)	86 (49)	0.333
Number of prior surgical resections
0	47 (78)	124 (71)	0.287
1	9 (15)	33 (19)	0.490
2	1 (2)	9 (5)	0.247
3 or more	3 (5)	8 (5)	0.899
Active smoker	22 (37)	54 (31)	0.422
Immediate post-operative baseline drug therapy
Metronidazole alone	9 (15)	29 (17)	0.763
Thiopurine	39 (65)	101 (58)	0.343
Adalimumab	12 (20)	44 (25)	0.408
CDAI > 150	40 (67)	113 (65)	0.673
CDAI > 200	30 (50)	90 (52)	0.465